Second Genome raises $42.6 mln Series B round

Second Genome Inc, the closely held South San Francisco biopharmaceutical company, closed a Series B investment round with $42.6 million in financing. The round was co-led by Pfizer Venture Investments and Roche Venture Fund. Participating were a number of new investors — Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, and the Mayo Clinic — as well as Series A investors Advanced Technology Ventures, Morgenthaler Ventures, Seraph Group, and individual investor Matthew Winkler, Ph.D. Second Genome has now raised a total investment of $59 million. With the new financing, Elaine Jones, executive director of Pfizer Venture Investments, and Carole Nuechterlein, head of Roche Venture Fund, will join the Second Genome board.

North AmericaUSBriefs